What baseline pulmonary function test values (forced expiratory volume in 1 second (FEV1), diffusing capacity for carbon monoxide (DLCO), total lung capacity (TLC), forced vital capacity (FVC), and FEV1/FVC ratio) are required to start bleomycin?

No Specific Baseline PFT Values Are Required to Start Bleomycin

There are no mandatory baseline pulmonary function test thresholds that must be met before initiating bleomycin therapy. 1

Key Guideline Recommendations

The 2018 British Journal of Cancer best-practice guidelines explicitly state that:

• Baseline PFTs should NOT be used in isolation to decide whether or not to treat with bleomycin 1
• PFTs cannot predict who will develop toxicity and are only weakly correlated with toxicity at the end of treatment 1
• Baseline PFTs are recommended "where possible" only as a reference point for comparison if toxicity develops later, not as a treatment prerequisite 1

What Actually Matters Before Starting Bleomycin

Instead of specific PFT cutoffs, focus on clinical risk factors:

Absolute Requirements:

• Age > 40 years: Baseline CT chest is mandatory (not PFTs) 1
• Clinical assessment for contraindications

Risk Factors Requiring Caution (but not absolute contraindications):

• Increasing age
• Significant smoking history
• Reduced renal function
• Pre-existing lung disease, particularly:
  • Pre-existing pulmonary fibrosis
  • Other symptomatic lung pathology
• Multiple risk factors compound the risk 1

The Evidence Behind This Approach

A prospective phase III randomized study—the highest quality evidence available—found that PFTs were only weakly correlated with increased toxicity and only at the end of treatment, not at baseline 1. This directly contradicts the utility of baseline PFTs for predicting who can safely receive bleomycin.

Practical Algorithm for Starting Bleomycin

1. Assess clinical risk factors (age, smoking, renal function, pre-existing lung disease)
2. If age > 40: Obtain baseline CT chest 1
3. Consider baseline PFTs (optional but recommended) as a reference for future comparison—not as a go/no-go decision tool 1
4. If multiple risk factors present: Exercise caution but no absolute contraindication exists 1

Common Pitfall to Avoid

Do not withhold bleomycin based solely on abnormal baseline PFT values. The guidelines are clear that PFTs should not be used to make treatment decisions 1. The decision to treat should be based on the clinical context, cancer prognosis, and overall risk-benefit assessment—not arbitrary PFT thresholds.

Role of PFTs During Treatment

While baseline values aren't required to start therapy, if you do obtain baseline PFTs, pay particular attention to DLCO as it shows the strongest (though still weak) correlation with subsequent toxicity 1, 2. However, even DLCO changes are not reliable for predicting toxicity prospectively.